References
- FerlayJSoerjomataramIErvikMGLOBOCAN 2012 v10, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 11LyonInternational Agency for Research on Cancer2013 Available from: http://globocan.iarc.fr
- SoerjomataramILortet-TieulentJParkinDMGlobal burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regionsLancet20123801840185023079588
- JemalACenterMMDeSantisCWardEMGlobal patterns of cancer incidence and mortality rates and trendsCancer Epidemiol Biomarkers Prev2010191893190720647400
- PatelJDKrilovLAdamsSClinical cancer advances 2013: annual report on progress against cancer from the American society of clinical oncologyJ Clin Oncol20143212916024327669
- KantarjianHMFojoTMathisenMZwellingLACancer drugs in the United States: Justum Pretium – the just priceJ Clin Oncol2013313600360423650428
- National Institute for Health and Clinical ExcellenceGuide to the Methods of Technology AppraisalLondonNational Institute for Health and Clinical Excellence (NICE)2008
- NeumannPJSandbergEABellCMStonePWChapmanRHAre pharmaceuticals cost-effective? A review of the evidence?Health Aff (Millwood)2000199210910718025
- SacristánJAOlivaJDel LlanoJPrietoLPintoJLWhat is an efficient health technology in Spain?Gac Sanit20021633434312113733
- KingJTJrTsevatJLaveJRRobertsMSWillingness to pay for a quality-adjusted life year: implications for societal health care resource allocationMed Decis Making20052566767716282217
- EllisLMBernsteinDSVoestEEAmerican society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomesJ Clin Oncol2014321277128024638016
- SlevinMLStubbsLPlantHJAttitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general publicBMJ1990300145814602379006
- BerrySRBellCMUbelPAContinental divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugsJ Clin Oncol2010284149415320697077
- NeumannPJPalmerJANadlerEFangCUbelPCancer therapy costs influence treatment: a national survey of oncologistsHealth Aff (Millwood)20102919620220048377
- GreenbergDHammermanAVinkerSShaniAYermiahuYNeumannPJOncologists’ and family physicians’ views on value for money of cancer and congestive heart failure careIsr J Health Policy Res201324424245811
- NadlerEEckertBNeumannPDo oncologists believe new cancer drugs offer good value?Oncologist200611909516476830
- KozminskiMANeumannPJNadlerESJankovicAUbelPAHow long and how well: oncologists’ attitudes toward the relative value of life-prolonging v quality of life-enhancing treatmentsMed Decis Making20113138038521088130
- UbelPABerrySRNadlerEIn a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survivalHealth Aff (Millwood)20123170971722492887
- GreenbergDHammermanAVinkerSShaniAYermiahuYNeumannPJWhich is more valuable, longer survival or better quality of life? Israeli oncologists’ and family physicians’ attitudes toward the relative value of new cancer and congestive heart failure interventionsValue Health20131684284723947979
- BraithwaiteRSMeltzerDOKingJTJrLeslieDRobertsMSWhat does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?Med Care20084634935618362813
- TowseAShould NICE’s threshold range for cost per QALY be raised? YesBMJ2009338b18119171561
- RafteryJShould NICE’s threshold range for cost per QALY be raised? NoBMJ2009338b18519171562
- ClaxtonKMartinSSoaresMMethods for the Estimation of the NICE Cost Effectiveness ThresholdYorkCentre for Health Economics; University of York201381
- NeumannPJCohenJTWeinsteinMCUpdating cost-effectiveness – the curious resilience of the $50,000-per-QALY thresholdN Engl J Med201437179679725162885
- GreenbergDEarleCFangCHEldar-LissaiANeumannPJWhen is cancer care cost-effective? A systematic overview of cost-utility analyses in oncologyJ Natl Cancer Inst2012102828820056956
- Camps-HerreroCPaz-AresLCodesMSocial value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologistsClin Transl Oncol20141691492024924625
- SacristánJAPatient-centered medicine and patient-oriented research: improving health outcomes for individual patientsBMC Med Inform Decis Mak201313623294526
- BaschEAbernethyAPMullinsCDRecommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncologyJ Clin Oncol2012304249425523071244
- RockeDJBeumerHWTaylorDHThomasSPuscasLLeeWTPhysician and patient and caregiver health attitudes and their effect on medicare resource allocation for patients with advanced cancerJAMA Otolaryngol Head Neck Surg2014140649750324763550
- RafteryJPPaying for costly pharmaceuticals: regulation of new drugs in Australia, England and New ZealandMed J Aust2008188262818205559
- RocchiAMenonDVermaSMillerEThe role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyondValue Health20081177178318179658
- National Institute for Health and Clinical ExcellenceAppraising Life-Extending, End of Life TreatmentsLondonNICE2009
- MoïsePFasslerPEstimating NICE’s cost-effectiveness threshold for end-of-life cancer treatments [abstract]Value Health201114A173
- LakdawallaDNJenaABDoctorJNCareful use of science to advance the debate on the UK cancer drugs fundJAMA2014311252624381964
- MarshallBCardonPPoddarADoes sample size matter in qualitative research?: a review of qualitative interviews in is researchJ Comput Inform Syst20135411122